Assembling the evidence…
Background Hereditary angioedema (HAE) is a rare genetic disorder with symptoms often appearing during childhood. Current approved long-term prophylaxis (LTP) for children aged <12 years requires parenteral administration. Berotralstat is an oral, small-molecule plasma kallikrein inhibitor, approved as prophylaxis of HAE attacks in patients aged 12 years or older. Objective To evaluate oral berotralstat for the LTP of HAE in pediatric patients through APeX-P (NCT05453968), the largest trial of LTP in patients with HAE aged 2 to <12 years. Methods Before berotralstat initiation, patients received standard of care for 12 weeks. Pharmacokinetics, safety, and efficacy of berotralstat were assessed in a planned interim analysis. Results Median (range) age of patients (N = 29) was 8.0 (3-11) years, with 48.3% female. Median age at symptom onset was 2.0 years, and 82.8% of patients reported symptom onset before 6 years. Steady-state berotralstat median (range) T max was 3.9 (0.9-6.0) hours, geometric mean (coefficient of variation) C max was 204 ng/mL (40%), and AUC 0-last was 915 ng•h/mL (42%). Most common treatment-emergent adverse events (AEs) were nasopharyngitis, upper respiratory tract infection, and headache. There were no drug-related grade 3/4 or serious AEs, deaths, or discontinuations related to AEs. Median (range) HAE attack rate during standard of care was 0.96 (0-5.0) attacks per 4-week period. Median (range) HAE attack rates for each 4-week period from day 1 to week 48 were 0 (week 4: 0-4.0; week 48: 0-1.7). Conclusion Oral berotralstat was well tolerated and resulted in early and sustained reductions in HAE attack rates. Trial Registration ClinicalTrials.gov Identifier: NCT05453968 and ClinicalTrialsRegister.eu Identifier: EU CTN 2024-511257-22-00.
Once-daily oral berotralstat treatment resulted in early and sustained reductions in HAE attack rates, attacks requiring on-demand treatment, days with angioedema symptoms, and health care resource utilization compared with the SOC period.
causal wording exceeds a single-arm, open-label before–after comparison with caregiver-reported outcomes
Oral berotralstat was safe and well tolerated in the pediatric HAE population.
interim adverse-event tabulation supports tolerability, though 29 participants and variable exposure limit broader safety inference
Median HAE attack rate decreased from 0.96 during SOC to 0 in each 4-week interval from week 4 through week 48 on berotralstat.
reported descriptive medians support the direction, while uncontrolled follow-up limits treatment attribution
Steady-state berotralstat median Tmax was 3.9 hours, geometric mean Cmax was 204 ng/mL, and AUC0-last was 915 ng•h/mL.
directly reported PK estimates from 141 samples in 24 participants across cohorts 1–3
Derived from the full evaluation — not a separate score.
Strengths
The report specifies weight-band dosing, steady-state sampling schedules, dose modifications, standardized AE grading, and safety monitoring. PK estimates are clearly scoped to the 24 patients in cohorts 1–3 because cohort 4 had reduced sampling.
↳ Methods, Study Design and Procedures; Results, Pharmacokinetics; eTable 1
The study addresses children aged 2 to under 12 years for whom the Introduction describes existing prophylactic options as parenteral. It contributes prospective evidence for an oral therapy already used in older patients.
↳ Abstract; Introduction, paragraphs 3–4; Objectives and End Points
The ongoing Phase III program connects the interim PK data to planned population modeling, weight-range selection, and matching pediatric exposure to established adult exposure. Continued follow-up through week 144 provides a defined development trajectory.
↳ Methods, Study Design; Discussion, opening paragraph; Conclusion
Limitations
Attack outcomes are compared with a preceding 12-week standard-of-care period without a concurrent control. The design cannot separate treatment effects from temporal variation, regression to the mean, or open-label expectation effects.
↳ Methods, Study Design and Statistical Analyses; Discussion, Limitations
The Abstract says treatment “resulted in” sustained reductions, while the final Discussion says the results “strongly support” reduced disease burden. Those formulations exceed the descriptive identification provided by the single-arm design.
↳ Abstract Conclusion; Discussion and Conclusion, pp. 687–688
Only 29 children were enrolled, 17 had completed at least 48 weeks at the interim cutoff, and the paper acknowledges a homogeneous racial population. These features limit confidence across demographic groups and longer exposure durations.
↳ Results, Patient Disposition; Figure 1; Table 1; Discussion, Limitations
The strongest elements are the pediatric PK and safety procedures, including weight-based cohorts, timed sampling, standardized AE grading, and transparent reporting of variable exposure. The efficacy results consistently show lower descriptive attack rates and symptom burden during treatment, but they arise from an open-label comparison with a preceding standard-of-care period. The Discussion acknowledges the lack of a comparator yet subsequently states that treatment demonstrated benefit and strongly supports reduced disease burden, which lowers clarity and context scores. The study therefore provides useful bridging evidence for dose selection and tolerability while leaving treatment-effect efficacy provisional.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.3
Confidence highThe study adds prospective pediatric PK, interim safety, and descriptive disease-burden data for an oral prophylactic option in children aged 2 to under 12 years. The advance is meaningful but incremental because efficacy is a secondary, uncontrolled comparison extending an established adult and adolescent program.
The primary objective of APeX-P was to describe the PK parameters of berotralstat administered orally to pediatric patients.
Weight-based cohorts, timed PK sampling, predefined attack-confirmation rules, AE grading, and transparent interim exposure support competent execution of the primary PK and safety objectives. The efficacy workup does not adequately examine regression to the mean or open-label expectation effects in caregiver-reported outcomes.
Patient-reported HAE attacks were programmatically confirmed or rejected for inclusion in the efficacy analyses.
The report is logically organized and its descriptive results are readily traceable to tables and figures. Headline phrases such as “resulted in” and “strongly support” imply treatment attribution beyond a single-arm, open-label comparison.
The results from APeX-P strongly support a reduction in disease burden.
The paper situates the trial within pediatric treatment guidelines, adult and adolescent berotralstat studies, and the pediatric lanadelumab literature. However, after acknowledging the absence of a comparator, it states that APeX-P demonstrated benefit and concludes with causal efficacy language, so the limitation is not carried through consistently.
In addition, this study does not use a comparator group.
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Caveats4 of 4 checks
Reported enrollment, disposition, PK, safety, and attack-rate figures reconcile across the text, tables, and figures. The principal concern is interpretive coherence between the uncontrolled design and causal efficacy wording in the headline conclusions.
Ethics approval, informed consent and assent, trial registration, sponsor involvement, and conflicts of interest are explicitly disclosed. Sponsor participation in design, analysis, and interpretation is relevant context but is not concealed or independently evidence of misconduct.
Flags: 3 declared / 5 total
23 of 23 checkable references verified
30 references in manuscript 7 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
This is an ongoing Phase III pediatric study of a drug already approved for patients aged 12 years or older, placing the work on a direct regulatory pathway. Readiness remains incomplete because the report is interim and the population PK model and longer follow-up are pending.
In a future analysis, the collected PK data will be incorporated into a population PK model.
AI-generated, human-governed. Something look off? Contact us to request a review.